logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Reata Pharmaceuticals Two Stories: Updated News of its Clinical Programs and Finances

Reata Pharmaceuticals Two Stories  Omaveloxolone in Patients with Friedreich’s Ataxia  Several communications between Reata Pharmaceuticals ( RETA ) and the FDA have taken place in the past regarding omaveloxolone for Friedreich’s Ataxia ( FA ) without reaching clear results that...

Read More

August 11, 2021

0

Amgen: Positive Results from Otezla® Phase 3 DISCREET Study in Moderate to Severe Genital Psoriasis

Amgen Announces Positive Results from Otezla Study for Psoriasis Amgen ( AMGN ) announced positive top-line results from the DISCREET trial - a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla® (apremilast) in adults with moderate...

Read More

December 2, 2021

0

A Biotechnology Company to Remember and Appreciate

Vir Biotechnology: What We've Learned from Dr. George Scangos George Scangos, PhD. is the chief executive officer of Vir Biotechnology ( VIR ) , we don't know if you remember him from our previous postings, so w e will remind...

Read More

August 12, 2021

0

Moderna Encouraging News. See Also: Translate Bio and Sanofi Good News

Moderna Presented Interim Clinical Data about mRNA-1273 for COVID-19 Moderna ( MRNA ) presented new Interim Clinical Data about its mRNA Vaccine ( mRNA-1273 )  against COVID-19 at the Advisory Committee on Immunization Practices ( ACIP ) Meeting. The presentation...

Read More

August 27, 2020

0

Akero Therapeutics Inc Q2 Business Updates and Financial Results

Akero Therapeutics Inc Akero Therapeutics Inc ( AKRO ) is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis ( NASH ), a disease without any approved therapies. Akero’s investigational drug product candidate, efruxifermin ( EFX ), is a...

Read More

August 13, 2021

0

Why The Time Has Come for Rhythm Pharmaceuticals to Outperform

Rhythm Pharmaceuticals Inc Rhythm Pharmaceuticals ( RYTM ) is a late-stage biopharmaceutical company with a product pipeline that reflects its focus of developing treatments for rare genetic obesity. The firm’s lead product, setmelanotide, is a melanocortin-4 receptor ( MC4R )...

Read More

August 28, 2020

0

Travere Therapeutics: Positive Trial Results of its Product Sparsentan in Treating IgA Nephropathy

Travere Therapeutics Sparsentan for IgAN Positive Results Phase 3 PROTECT Study of  Travere Therapeutics ( TVTX ) product sparsentan for the treatment of IgA nephropathy ( IgAN ) demonstrated positive topline interim results. The PROTECT Study met its pre-specified interim...

Read More

August 16, 2021

0

Moderna Inc Stock is Tanking After Rallying

Moderna Inc Late August Announcements  On August 28, 2020 Moderna Inc ( MRNA ) issued a press release confirming that the Company is engaged in discussions with the Ministry of Health, Labor and Welfare of Japan ( MHLW ) to...

Read More

September 1, 2020

0

Ionis Pharmaceuticals to Collaborate with AstraZeneca in Treating Transthyretin Amyloidosis with Ionis Product Eplontersen

Ionis Pharmaceuticals and AstraZeneca in Collaboration to Treat ATTR with Eplontersen Ionis Pharmaceuticals ( IONS ) announced entering into a strategic collaboration agreement with AstraZeneca ( AZN ) to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of...

Read More

December 8, 2021

0

From Inovio: Thermo Fisher Scientific Will Manufacture the Inovio COVID-19 Vaccine Candidate

Inovio COVID-19 Vaccine Candidate Will be Manufactured by Thermo Fisher Scientific Thermo Fisher Scientific ( TMO ) joins other contract development and manufacturing organizations in Inovio's global manufacturing consortium enabling Inovio ( INO ) to potentially scale INO-4800. With its...

Read More

September 9, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 28
  • 29
  • 30
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy